Summary:
In adults with early-onset type 2 diabetes (T2D) compared to those with later-onset T2D in a post hoc analysis of the SURPASS clinical trials (n=3,792), tirzepatide, a dual GIP and GLP-1 receptor agonist, administered over 40–52 weeks significantly improved HbA1c (-2.6% vs. -2.4%), body weight (-14 kg vs. -13 kg), waist circumference (-10 cm vs. -10 cm), triglycerides (-26% vs. -24%), HDL cholesterol (+7% vs. +7%), and systolic blood pressure (-6 mmHg vs. -7 mmHg) compared to individuals with later-onset T2D receiving tirzepatide under identical settings, though early-onset T2D individuals exhibited worse metabolic profiles at baseline. Tirzepatide demonstrated robust efficacy regardless of age at T2D onset.
| PICO | Description |
|---|---|
| Population | Adults with early-onset type 2 diabetes (T2D) compared to those with later-onset T2D in a post hoc analysis of the SURPASS clinical trials (n=3,792). Included groups were characterized by differences in age at diagnosis, diabetes duration, metabolic health, and baseline glycemic levels. |
| Intervention | Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, administered in clinical trials SURPASS-1, SURPASS-2, and SURPASS-3 over 40–52 weeks to improve glycemic control and metabolic markers. |
| Comparison | Individuals diagnosed with later-onset T2D within the same SURPASS clinical trials receiving tirzepatide under identical settings and monitoring for glycemic, weight, and cardiometabolic markers. |
| Outcome | Both groups experienced significant and comparable improvements in HbA1c (-2.6% vs. -2.4%), body weight (-14 kg vs. -13 kg), waist circumference (-10 cm vs. -10 cm), triglycerides (-26% vs. -24%), HDL cholesterol (+7% vs. +7%), and systolic blood pressure (-6 mmHg vs. -7 mmHg). Despite younger age, early-onset T2D individuals displayed worse metabolic profiles at baseline. Tirzepatide demonstrated robust efficacy irrespective of the age at T2D onset. |
Source: Philip Zeitler, et al. “Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.” Diabetes Care. Read article here.
